News | Heart Valve Technology | September 19, 2016

Valtech Cardio Presents Data on Tricuspid, Mitral Devices at PCR London Valves 2016

Initial clinical experience of several Cardioband Tricuspid implantations and two-year follow-up results of mitral patients to be presented

Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data

September 19, 2016 — Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at PCR London Valves 2016, Sept. 18-20. In addition, updated two-year follow-up results of the multi-center Cardioband Mitral study will be presented at the meeting.

“I am pleased to share my first experience with Cardioband Tricuspid, which shows that it is feasible to perform a successful trans-venous surgical like annuloplasty procedure for the treatment of TR.” said Francesco Maisano, M.D, chairman and professor of cardiovascular surgery at The University Hospital of Zurich who successfully performed the first implantation of Cardioband Tricuspid. “The device has the potential to reproduce surgical standards, although our experience is still limited at the moment.”

A Valtech symposium titled, “Cardioband: Clinical Reality for Mitral and Tricuspid Valve Repair,” will be led by Eberhard Grube, M.D., Ph.D., (University of Bonn, Germany) and Karl-Heinz Kuck, M.D. (Asklepios Klinic St. Georg, Hamburg, Germany) Tuesday, Sept. 20. Panelists will discuss how they are successfully using Cardioband to apply the surgical gold standard in a transfemoral approach.

An accepted talk, “Direct annuloplasty - Cardioband in tricuspid regurgitation,” was presented by Prof. K.H. Kuck (Asklepios Klinic St. Georg, Hamburg, Germany) as part of the “innovation in percutaneous tricuspid valve intervention” session Sunday, Sept. 18.

An accepted abstract, "One Year Follow-up Results of Mitral Valve Transcatheter Annuloplasty System for Mitral Reconstruction Multicentre Trial,” will be presented by Prof. R. S. von Bardeleben (University of medicine Mainz Germany) as part of the "Mitral and Tricuspid Valve Interventions" session held Monday, Sept. 19.

An additional accepted abstract, "Cardioband implantation to treat recurrent mitral regurgitation after MitraClip therapy,” will be presented by Dr. M. Taramasso (University Hospital of Zurich) as part of the "Percutaneous mitral therapies" session Tuesday, Sept. 20.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init